Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Toddlers 11-18 months of age (from the 11th month birthday to one day prior to the 19th month birthday) who previously received the primary immunisation series with a hexavalent vaccine (consisting of three doses of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenza type b combined vaccine administered within the first 6 months of life)~* Informed consent form signed by both parents or by the legal guardian~* Parents or a legal guardian able to read and write the local language~* Parents or a legal guardian able to attend all scheduled visits and to comply with the study procedures.~Exclusion Criteria:~* Presence of fever (defined as rectal body temperature ≥ 38.0°C) reported within the last 72 hours~* Moderate or severe acute illness with or without fever~* Participation in another clinical trial in the 30 days preceding study vaccination~* Planned participation in another clinical trial during the present study period~* Immunisation with a pneumococcal vaccine prior to study vaccination or planned during the participation in the study~* Received more than 3 doses of a hexavalent vaccine prior to study vaccination~* Received any vaccination in the 30 days preceding the trial~* History of serological/microbiologically-confirmed diagnosis of infection due to pertussis, tetanus, diphtheria, poliomyelitis, hepatitis B, Haemophilus influenzae type b and/or Streptococcus pneumoniae~* Congenital or acquired humoral/cellular immunodeficiency or immunosuppressive therapy such as long-term systemic corticosteroids therapy (≥ 2 mg/kg/day prednisone equivalent for ≥ 14 days in the 30 days prior to study vaccination)~* Systemic or local hypersensitivity to any of the study vaccine components (including neomycin, streptomycin, polymyxin B and formaldehyde)~* History of a life-threatening reaction (such as encephalopathy, Hypotonic-Hyporesponsive Episode (HHE), rectal body temperature ≥ 40.0°C, convulsions with or without fever) to any vaccine containing the same components as the study vaccines~* Blood or blood-derived products (immunoglobulins) received during 3 months prior to study vaccination~* Known HIV seropositivity~* Known thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination~* History of encephalopathy, seizures or progressive, evolving or unstable neurological condition~* Clinically significant findings on review of systems that might interfere with study vaccination or which, in the opinion of the Investigator, would interfere with the evaluation of the study vaccine/objectives or pose a health risk to the subject.

- Gender: ALL
- Minimum Age: 11 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Participants will receive PEDIACEL with Prevenar at Visit 1 and ENGERIX-B Kinder at Visit 2
- Group 2 (Type: ACTIVE_COMPARATOR): Participants will receive Infanrix hexa with Prevenar at Visit 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete